RxDoctor Payments Data

Kristopher Arndt, MD

Pulmonary Disease · Lynchburg, VANPI 1881147056

Payments from drug & device makers

$3,588in general payments, 2019–2025

Across 63 payments — averaging $56.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • GSK$274
  • Sanofi$269
  • Pulmonx Corporation$146
  • AstraZeneca$122
  • Jazz Pharmaceuticals Inc.$101
  • plus $362 from 9 others

What the payments were for

  • Travel & lodging$72320%
  • Food & beverage$1,27636%
  • Education$1,58944%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,588 in reported general payments places this provider in the 50th percentile of 317 pulmonary disease providers in Virginia.

See all pulmonary disease providers in Virginia

Medicare billing

Part B allowed, 2024
$86,243
Medicare patients
374
Services billed
841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter114$118,807
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr52$37,590
Spiriva RespimatTiotropium Bromide42$25,350
Stiolto RespimatTiotropium Br/Olodaterol Hcl32$22,271
EliquisApixaban17$17,221
Incruse ElliptaUmeclidinium Bromide18$10,468
SymbicortBudesonide/Formoterol Fumarate16$8,482
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$4,434
Albuterol Sulfate HfaAlbuterol Sulfate120$3,940
Wixela InhubFluticasone Propion/Salmeterol11$1,764
Mycophenolate Mofetil12$861
Ipratropium Bromide11$642
Fluticasone Propionate38$599
Montelukast Sodium27$272
Pantoprazole Sodium26$225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$274$166,866184 claims
PfizerEliquis$54$17,22117 claims
AstraZenecaSymbicort$122$8,48216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 317 pulmonary disease providers in Virginia.

Other pulmonary disease in Lynchburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →